Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601)Atsushi Nakamura, Shunichi Sugawara, Ryota Saito et al.|The Oncologist|2020Cited by 6